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INTRODUCTION 
The oral route is considered as the most promising route 
of drug delivery. Effective oral drug delivery may 
depend upon the factors such as gastric emptying 
process, gastrointestinal transit time of dosage form, drug 
release from the dosage form and site of absorption of 
drugs 1,2. Floating multiparticulate are gastro-retentive 
drug delivery systems based on non-effervescent and 
effervescent approach. Hollow microspheres are in strict 
sense, spherical empty particles without core. These 
microspheres are characteristically free flowing powders 
consisting of proteins or synthetic polymers, ideally 
having a size less than 200 micrometer.3 
Gastroretentive systems can remain in the gastric region 
for several hours and hence significantly prolong the 
gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, 
and improves solubility for drugs that are less soluble in 
a high pH environment.4 
It is a formulation of a drug with gel forming 
hydrocolloids meant to remain buoyant in the stomach 
contents. Drug dissolution and release from the dosage 
form retained in the stomach fluids occur at the pH of the 
stomach under fairly controlled conditions5.  
SUITABLE DRUG CANDIDATES FOR GASTRO 
RETENTION
 6
 
In general, appropriate candidates for gastroretentive 
dosage form are molecules that have poor colonic 
absorption but are characterized by better absorption 
properties at the upper parts of the GIT:  
 Narrow absorption window in GI tract, e.g., 
riboflavin and levodopa 
 Primarily absorbed from stomach and upper part of 
GI tract, e.g., calcium supplements, 
chlordiazepoxide and cinnarazine 
 Drugs that act locally in the stomach, e.g., antacids 
and misoprostol 
 Drugs that degrade in the colon, e.g., ranitidine HCl 
and metronidazole 
 Drugs that disturb normal colonic bacteria, e.g., 
amoxicillin trihydrate 
CLASSIFICATION OF DRUG DELIVERY 
SYSTEM 
A. Single Unit Floating Dosage Systems 
 a) Effervescent Systems (Gas-generating Systems) 
 b) Non-effervescent Systems  
B. Multiple Unit Floating Dosage System 
 a) Effervescent Systems (Gas-generating Systems) 
 b) Non-effervescent Systems  
 c) Hollow Microspheres 
C. Raft forming system 
A. Single Unit Floating Dosage Systems  
Single unit dosage forms are easiest to develop but 
suffers from the risk of losing their effects too early due 
to their all or none emptying from the stomach and, thus 
they may cause high variability in bioavailability and 
local irritation due to large amount of drug delivered at a 
particular site of the gastro intestinal tract7. 
a) Effervescent Systems (Gas-generating Systems)  
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These are matrix types of systems prepared with the help 
of swellable polymers such as methylcellulose and 
chitosan and various effervescent compounds, e.g. 
sodium bicarbonate, tartaric acid, and citric acid. They 
are formulated in such a way that when in contact with 
the acidic gastric contents, CO2 is liberated and gets 
entrapped in swollen hydrocolloids, which provides 
buoyancy to the dosage forms8.  
 
Figure 1: Working principle of effervescent floating 
drug delivery system 
b) Non-effervescent Systems 
Non-effervescent floating dosage forms use a gel 
forming or swellable cellulose type hydrocolloids, 
polysaccharides, and matrix forming polymers like 
polycarbonate, polyacrylate, polymethacrylate, and 
polystyrene. The formulation method includes a simple 
approach of thoroughly mixing the drug and the gel-
forming hydrocolloid. After oral administration this 
dosage form swells in contact with gastric fluids and 
attains a bulk density of < 1. The air entrapped within the 
swollen matrix imparts buoyancy to the dosage form. 
The so formed swollen gel-like structure acts as a 
reservoir and allows sustained release of drug through 
the gelatinous mass. Excipients used most commonly in 
these systems include hydroxypropyl methyl cellulose 
(HPMC), polyacrylate polymers, polyvinyl acetate, 
Carbopol, agar, sodium alginate, calcium chloride, 
polyethylene oxide and polycarbonate9. 
B. Multiple Unit Floating Dosage Systems  
Multiple unit dosage forms may be an attractive alternate 
since they have been shown to reduce inter and 
intra‐ subject variabilities in drug absorption as well as 
to lower the possibility of dose dumping. Various 
multiple unit floating systems have been developed in 
different forms, and using principles such as air 
compartment multiple unit system, hollow microspheres 
prepared by emulsion solvent diffusion method, beads 
prepared by emulsion gelation method. Use of 
effervescent and swellable polymer is another approach 
for preparing multiple unit FDDS10. 
a) Effervescent Systems 
A multiple unit system comprises of calcium alginate 
core and calcium alginate/PVA membrane, both 
separated by an air compartment was prepared. In 
presence of water, the PVA leaches out and increases the 
membrane permeability, maintaining the integrity of the 
air compartment. Increase in molecular weight and 
concentration of PVA, resulted in enhancement of the 
floating properties of the system. Freeze‐ drying 
technique is also reported for the preparation of floating 
calcium alginate beads. Sodium alginate solution is 
added drop wise into the aqueous solution of calcium 
chloride, causing the instant gelation of the droplet 
surface, due to the formation of calcium alginate. The 
obtained beads are freeze‐ dried resulting in a porous 
structure, which aid in floating. The authors studied the 
behavior of radiolabeled floating beads and compared 
with nonfloating beads in human volunteers using 
gamma scintigraphy. Prolonged gastric residence time of 
more than 5.5 h was observed for floating beads. The 
nonfloating beads had a shorter residence time with a 
mean onset emptying time of 1 hr11.  
        
    
Figure 2: (a) A multi-unit oral floating dosage system. 
(b) Stages of floating mechanism: (A) penetration of 
water; (B) generation of CO2 and floating; (C) 
dissolution of drug. Key: (a)conventional SR pills; (b) 
effervescent layer; (c)swellable layer; (d) expanded 
swellable membrane layer; (e) surface of water in the 
beaker (37
0
C). 
c) Non-effervescent Systems  
No much report was found in the literature on 
effervescent multiple unit systems, as compared to the 
effervescent systems. However, few workers have 
reported the possibility of developing such system 
containing indomethacin, using chitosan as the polymeric 
excipient. A multiple unit HBS containing indomethacin 
as a model drug prepared by extrusion process is 
reported. A mixture of drug, chitosan and acetic acid is 
extruded through needle, and the extrudate is cut and 
dried. Chitosan hydrates and floats in the acidic media, 
required drug release could be obtained by modifying the 
drug-polymer ratio12. 
d) Hollow Micro spheres 
Hollow microspheres loaded with drug in their outer 
polymer shelf were prepared by a novel emulsion solvent 
diffusion method. The ethanol/dichloromethane solution 
of the drug and an enteric acrylic polymer was poured 
into an agitated solution of Poly Vinyl Alcohol (PVA) 
that was thermally controlled at 400C. The gas phase is 
generated in the dispersed polymer droplet by the 
evaporation of dichloromethane formed and internal 
cavity in the microsphere of the polymer with drug. The 
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microballoon floated continuously over the surface of an 
acidic dissolution media containing surfactant for more 
than 12 hrs13,14. 
 
 
                                                         Figure 3: Formulation of floating microspheres 
C. Raft forming system 
Here, a gel-forming solution (e.g. Sodium alginate 
solution containing carbonates or bicarbonates) swells 
and forms a viscous cohesive gel containing entrapped 
CO2 bubbles on contact with gastric fluid. Formulations 
also typically contain antacids such as aluminium 
hydroxide or calcium carbonate to reduce gastric acidity. 
Because raft forming systems produce a layer on the top 
of gastric fluids, they are often used for gastro-
oesophageal reflux treatment 15, 16. 
MECHANISM OF FLOATING SYSTEMS 
Floating drug delivery systems (FDDS) have bulk 
density lesser than gastric fluids, so they remain buoyant 
in the stomach without affecting the gastric emptying 
rate for a prolonged period of time. While the system is 
floating on the gastric contents, the drug is released 
slowly at the desired rate from the system. However, 
besides a minimal gastric content needed to allow the 
proper achievement of the buoyancy retention principle, 
a minimal level of floating force (F) is also required to 
keep the dosage form reliably buoyant on the surface of 
the meal. To measure the floating force kinetics, a novel 
apparatus for determination of resultant weight has been 
reported in the literature. The apparatus operates by 
measuring continuously the force equivalent to F (as a 
function of time) that is required to maintain the 
submerged object. This apparatus helps in optimizing 
FDDS with respect to stability and durability of floating 
forces produced in order to prevent the drawbacks of 
unforeseeable intragastric buoyancy capability 
variations17.    
ADVANTAGES OF FLOATING DRUG DELIVERY 
SYSTEMS   
Floating dosage systems form important technological 
drug delivery systems with gastric retentive behavior and 
offer several advantages in drug delivery. These 
advantages include: 
1. FDDS can remain in the stomach for several hours and 
therefore prolong the gastric retention time of various 
drugs18.  
2. FDDS are advantageous for drugs meant for local 
action in the stomach eg: Antacids 
3. FDDS dosage forms are advantageous in case of 
vigorous intestinal movement and in diarrhea to keep the 
drug in floating condition in stomach to get a relatively 
better response. 
4. FDDS improves patient compliance by decreasing 
dosing frequency19. 
5.  Bioavailability  enhances  despite  first  pass  effect 
because  fluctuations  in  plasma  drug  concentration  are  
avoided;  a  desirable  plasma  drug  concentration is 
maintained by continuous drug release20. 
6. Acidic substance like aspirin causes irritation on the 
stomach wall when come in contact with it hence; 
HBS/FDDS formulations may be useful for the 
administration of aspirin and other similar drugs.  
7. The FDDS are advantageous for drugs absorbed 
through the stomach eg: Ferrous salts, Antacids. 
Improved drug absorption, because of increased GRT 
and more time spent by the dosage form at its absorption 
site. 
8. Site-specific drug delivery21.   
LIMITATIONS OF GASTRORETENTIVE DRUG 
DELIVERY SYSTEMS
 
1. Drugs which are irritating the gastric mucosa are also 
not suitable. 
2. The drug substances that are unstable in the acidic 
environment of the stomach are not suitable candidates 
to be incorporated in the systems. 
3.  Not suitable for drugs that have solubility or stability 
problem in GIT22. 
4. The drugs that are significantly absorbed through out 
gastrointestinal tract, which undergo significant first pass 
metabolism, are only desirable candidate23.  
5. The ability to float relies on the hydration state of the 
dosage form. In order to keep these tablets floating, 
intermittent administration of water is beneficial24.  
EVALUATION OF FLOATING DRUG DELIVERY 
SYSTEMS 
1. Determination of hardness of tablet:- Randomly 
sampled twenty tablets in each batch of formulations 
should be used for the determination of hardness with the 
help of Monsanto type hardness tester25. 
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2.  Determination of weight variation:- Twenty tablets 
selected at the random are weighed accurately and the 
average weight of the tablet is calculated. Then the 
deviation of individual weight from the average weight is 
calculated. 
 3. Determination of thickness of the tablet:- The 
individual crown  to  crown thickness of ten tablets is 
determined using slide calipers for each batch26. 
 4. Floating lag time: It is the time taken by the tablet to 
emerge on to the surface of dissolution medium and is 
expressed in seconds or minutes27. 
4. Measurement of Floating Capacity: - Three 
individual tablets are put in individual flask containing 
400ml of 0.1(N) HCL solutions. Then the time in 
minutes for each tablets to go from the bottom to the top 
of the flask (floating lag time) and the time for which 
tablets constantly float on the water surface (duration of 
floating) are measured. The sample mean and standard 
deviation are then calculated28. 
5. Angle of repose:- The frictional forces in a loose 
powder or granules can be measured by angle of repose. 
This is the maximum angle possible between the surface 
of a pile of powder or granules and the horizontal plane.  
The granules were allowed to flow through the funnel 
fixed to a stand at definite height (h). The angle of repose 
was then calculated by measuring the height and radius 
of the heap of granules formed29. 
tan θ = h/r 
 θ = tan-1 (h/r) 
θ = angle of repose 
h = height of the heap 
r = radius of the heap 
8. Determination of In Vitro Dissolution Study 
The test for buoyancy and in vitro drug release studies 
are usually carried out in simulated gastric and intestinal 
fluids maintained at 37oC. In practice, floating time is 
determined by using the USP dissolution apparatus 
containing 900ml of 0.1 HCl as a testing medium 
maintained at 37oC. The time required to float the HBS 
dosage form is noted as floating (or floatation) time30.  
CONCLUSION  
Drug absorption in the gastrointestinal tract is a highly 
variable procedure and prolonging gastric retention of 
the dosage form extends the time for drug absorption. 
Drug absorption in the gastrointestinal tract is a highly 
variable process and prolonging gastric retention of the 
dosage form extends the time for drug absorption. Thus 
gastro retentive dosage forms provide an additional 
advantage for drugs that are absorbed primarily in the 
upper segments of gastrointestinal tract. 
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